Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors

Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors Publisher Pubmed

Ghahrisaremi N¹ ; Akbari B¹ ; Soltantoyeh T¹ ; Hadjati J¹ ; Ghassemi S² ; Mirzaei HR¹

Source: Frontiers in Immunology Published:2021

Abstract

Chimeric antigen receptor (CAR) T cell therapy has shown unprecedented success in treating advanced hematological malignancies. Its effectiveness in solid tumors has been limited due to heterogeneous antigen expression, a suppressive tumor microenvironment, suboptimal trafficking to the tumor site and poor CAR T cell persistence. Several approaches have been developed to overcome these obstacles through various strategies including the genetic engineering of CAR T cells to blunt the signaling of immune inhibitory receptors as well as to modulate signaling of cytokine/chemokine molecules and their receptors. In this review we offer our perspective on how genetically modifying cytokine/chemokine molecules and their receptors can improve CAR T cell qualities such as functionality, persistence (e.g. resistance to pro-apoptotic signals) and infiltration into tumor sites. Understanding how such modifications can overcome barriers to CAR T cell effectiveness will undoubtedly enhance the potential of CAR T cells against solid tumors. © Copyright © 2021 Ghahri-Saremi, Akbari, Soltantoyeh, Hadjati, Ghassemi and Mirzaei.

Related Docs

View other Related Docs

1. The Inhibitory Receptors Pd1, Tim3, and A2ar Are Highly Expressed During Mesocar T Cell Manufacturing in Advanced Human Epithelial Ovarian Cancer, Cancer Cell International (2023)

2. The Art of Bioimmunogenomics (Bigs) 5.0 in Car-T Cell Therapy for Lymphoma Management, Advanced Pharmaceutical Bulletin (2024)

3. Car T Cells and Metabolic Programming: A Review, Medical Immunology (Russia) (2025)

Experts (# of related papers)

View all Related Experts

Hamid Reza Mirzaei (7)

Jamshid Hadjati (7)

Style	Citing Format
MLA	Ghahrisaremi N, et al.. "Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors." Frontiers in Immunology, vol. 12, no. , 2021, pp. -.
APA	Ghahrisaremi N, Akbari B, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR (2021). Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors. Frontiers in Immunology, 12(), -.
Chicago	Ghahrisaremi N, Akbari B, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. "Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors." Frontiers in Immunology 12, no. (2021): -.
Harvard	Ghahrisaremi N et al. (2021) 'Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors', Frontiers in Immunology, 12(), pp. -.
Vancouver	Ghahrisaremi N, Akbari B, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors. Frontiers in Immunology. 2021;12():-.
BibTex	@article{ author = {Ghahrisaremi N and Akbari B and Soltantoyeh T and Hadjati J and Ghassemi S and Mirzaei HR}, title = {Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors}, journal = {Frontiers in Immunology}, volume = {12}, number = {}, pages = {-}, year = {2021} }
RIS	TY - JOUR AU - Ghahrisaremi N AU - Akbari B AU - Soltantoyeh T AU - Hadjati J AU - Ghassemi S AU - Mirzaei HR TI - Genetic Modification of Cytokine Signaling to Enhance Efficacy of Car T Cell Therapy in Solid Tumors JO - Frontiers in Immunology VL - 12 IS - SP - EP - PY - 2021 ER -

Science Communicator Platform

Authors

Abstract